

Electronic Acknowledgement Receipt

EFS ID:	7735419
Application Number:	09993647
International Application Number:	
Confirmation Number:	1010
Title of Invention:	omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
First Named Inventor/Applicant Name:	Bernd Riedl
Customer Number:	23599
Filer:	Csaba Henter/Caitlin Sickler
Filer Authorized By:	Csaba Henter
Attorney Docket Number:	BAYER 18A
Receipt Date:	03-JUN-2010
Filing Date:	27-NOV-2001
Time Stamp:	10:00:00
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	P168a-Manenti-et-al-Mol-Cancer-Ther-v4-n5-p715.pdf	4496641 112313d2f4a7bf84407d155bc4926ba80cfb a203	no	11

Warnings:

Information:

2	NPL Documents	P169- MannovaetalActivationofNRasP 13K.pdf	831706 dacfb4ec5241154ecc3b173e4bd1ed57c7b54a48	no	8
Warnings:					
Information:					
3	NPL Documents	P170- MarkgrafStrainedHeterocyclicS ystems.PDF	365292 10de5a739f974a7bbac68edca5f700ed732b43d5	no	6
Warnings:					
Information:					
4	NPL Documents	P171-MARSHALL-MAPKinase-1. pdf	843258 df6ed177189eed2bb42d767b72b2332f001f3210	no	8
Warnings:					
Information:					
5	NPL Documents	P171a- MarxJWhyaNewCacerDrug.PDF	268791 4c7c26afab2a28d149d7470e5bf35a1a8b7da4b1	no	2
Warnings:					
Information:					
6	NPL Documents	P172- McGoonScreeningEarlyDetecti on.PDF	2563567 648f2a330fb36666cf920bfccef3203a986ce31f	no	22
Warnings:					
Information:					
7	NPL Documents	P172a-Medinger2006.pdf	759959 e8dbc277828eea6307457a9cc1f28fd541fba1da	no	5
Warnings:					
Information:					
8	NPL Documents	P172b- MedReportDeutschlandSorafenib zurTherapie.pdf	102185 356e2b074bf99f4ae844cd5732890ef9e490c4b3	no	1
Warnings:					
Information:					
9	NPL Documents	P173-Meuillet- InVivoMolecular2004.pdf	461028 f0420b413ddb4d3c9c96d50c54dae7acd341a672	no	16
Warnings:					
Information:					
10	NPL Documents	P174-Michaelis-JLACBF1913. pdf	267122 2515eda02f6efab5d9560322ddd41174ef36e48	no	2
Warnings:					
Information:					

11	NPL Documents	P174a-Milanini-et-al-J-Biol-Chem-v273-p18165.pdf	423987 4e1ee8c6957b974950039ffb9f176684463a5395	no	8
Warnings:					
Information:					
12	NPL Documents	P175-MILANOETAL-NewMolecularTargetedTherapies.pdf	1254679 d1d91e191d95a529f5b7c99cea515ee55ad8e1e2	no	11
Warnings:					
Information:					
13	NPL Documents	P175a-Mills-et-al-Clin-Cancer-Res-v10-p4998.pdf	1181202 04d022c876b108084336471410d8fdadeb1ef611	no	6
Warnings:					
Information:					
14	NPL Documents	P175b-Milojkovic-et-al-Blood-v104-Abstract-1999.pdf	191145 47d4429c03c3b11c19d37981976fe1f6afe9f242	no	3
Warnings:					
Information:					
15	NPL Documents	P175c-MinnaetalABullsEyeforTargetedLungCancer.PDF	354599 0312c8ace88cc304b9a4f5aa7f9838b3af16de85	no	3
Warnings:					
Information:					
16	NPL Documents	P176-MITAETAL-MolecularTargetRapamycin.pdf	1051370 3f3e6d8e4ed6d2fe6e787207da07e9dfc553daed	no	9
Warnings:					
Information:					
17	NPL Documents	P177-MoellingSignalTransductionasTargetofGeneTherapy.pdf	845713 d854d5f274e66f19e2dee584ac485e9b3f958363	no	9
Warnings:					
Information:					
18	NPL Documents	P178-Molhoek-SynergisticInhibitionOfHuman.pdf	781066 7b09282a4f81edd83e676958ddd85ebac88fee	no	11
Warnings:					
Information:					
19	NPL Documents	P179-Monia-FirstSecondGeneration.pdf	877415 b1e551303641fe5feb11f2ecdde3757c73d95631	no	9
Warnings:					
Information:					

20	NPL Documents	P180- MoniaetalAntitumorActivityofa PhosphorothioateAntisenseOli godeoxy.pdf	956084 07dd791146b938e9e3fd74681cc29004a2d 46124	no	8
----	---------------	---	--	----	---

Warnings:

Information:

Total Files Size (in bytes):

18876809

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.